Table 2.

Antiretroviral use and risk ratios for development of NHL in subjects after starting newer-class antiretroviral regimens

Antiretroviral	NHL cases (n = 5)	Controls (n = 73)	Unadjusted Odds Ratio	95% CI
Nucleos(t)ide reverse transcriptase inhibitors	100%	97%	NC	(p = 1.0)
Raltegravir	100%	86%	NC	(p = 1.0)
Etravirine	20%	53%	0.29	0.02-2.0
Maraviroc	0	11%	0
Darunavir/ritonavir	80%	59%	2.8	0.30-26.6
Enfuvirtide	20%	4%	5.8	0.40-69.5

NC: not calculated